CRDF
NASDAQ
US
Cardiff Oncology, Inc. - Common Stock
$1,58
▼ $-0,03
(-1,86%)
Vol. 529K
5
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$189.3M
ROE
-77,5%
Margine
-10106,8%
D/E
0,00
Beta
1,32
52W
$2–$5
Consenso Wall Street
14 analisti · Apr 20263
Acquisto forte
9
Compra
2
Mantieni
0
Vendi
0
Vendita forte
85,7%
Rating Compra
Grafico dei Prezzi
Titoli simili
PEPG
PepGen Inc
$447.6M
GNLX
Genelux Corp
$165.9M
SGMO
Sangamo Therapeutics Inc
$141.3M
BMEA
Biomea Fusion Inc
$87.7M
KPTI
Karyopharm Therapeutics Inc
$125.5M
CADL
Candel Therapeutics Inc
$310.2M
ALDX
Aldeyra Therapeutics Inc
$99.9M
SPRB
Spruce Biosciences, Inc
$93.2M
COYA
Coya Therapeutics Inc
$121.4M
Utili
Tasso di battuta: 50,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $-0,19 | $-0,11 | +$0,08 |
| Set 2025 | $-0,21 | $-0,17 | +$0,04 |
| Giu 2025 | $-0,20 | $-0,21 | $-0,01 |
| Mar 2025 | $-0,19 | $-0,20 | $-0,01 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $151K | $109K | $121K | $120K | $243K |
| Utile netto | — | -$11.8M | -$13.4M | -$13.9M | -$11.3M | -$7.2M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -78.6% | -77.9% | -77.9% | -77.9% | -77.2% | -77.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -11523.1% | -9344.1% | -9344.1% | -9344.1% | -10064.3% | -10106.8% |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 4.42 | 4.42 | 4.42 | 4.42 | 4.20 | 4.20 |
Rapporti chiave
ROA (TTM)
-63,0%
P/S (TTM)
377,81
P/B
3,5
EPS (TTM)
$-0,80
CF/Share
$-0,91
Crescita ricavi 3A
+23,8%
52W High
$4,99
52W Low
$1,90
$1,90
Intervallo 52 settimane
$4,99
Salute finanziaria
Flusso di cassa libero
-$6.0M
Debito netto
-$16.6M
Liquidità
$17.5M
Debito totale
$832K
Aggiornato al Dic 31, 2025
Як CRDF виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка CRDF vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
377,8
▲
2840%
sopra
peer
(12,9)
vs Peer
vs Settore
Sopravvalutato
P/B
3,5
▲
41%
sopra
peer
(2,5)
vs Peer
vs Settore
Più costoso
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість CRDF vs аналоги Biotechnology
ROE
-77,5%
▼
15%
sotto
peer
(-67,3%)
vs Peer
vs Settore
In linea
Net margin
-10106,8%
▼
3425%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Debole
Валова маржа
100,0%
▲
27%
sopra
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
-63,0%
▼
35%
sotto
peer
(-46,7%)
vs Peer
vs Settore
Debole
Фінансове здоровʼя CRDF vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
4,2
▼
5%
sotto
peer
(4,4)
vs Peer
vs Settore
In linea
Beta
1,3
▲
36%
sopra
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів CRDF
CRDF
Mediana peer
Industria
CRDF прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CRDF vs аналоги: ключові метрики
Principali azionisti
Top 5: 21,62%Blackrock Inc.
5,91%
$6.3M
Vanguard Group Inc
5,44%
$5.8M
Laurion Capital Management,…
3,87%
$4.1M
Pfizer Inc
3,53%
$3.7M
Acorn Capital Advisors, LLC…
2,87%
$3.0M
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora